Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (319)	9/10/1997 2:08:00 PM
From: Bill Tomko	of 834

page 29 2'd para of the red herring; para beginning,"Synthelabo will evaluate-----" Why the slippage in reporting the clinical results? The Herirng says results to be reported by 12/31/97. When TXb reported thier portion of the ARG-230 trial in , I think , March 1997 they said Synthelabo would report in the summer of 1997 the results of thier higher dose (ARGAMI-2) study. Why the delay and what does it mean?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next